List view / Grid view

News

IMBRUVICA™ (ibrutinib) capsules now approved in the U.S. for Mantle Cell Lymphoma patients who have received at least one prior therapy

13 November 2013 | By Johnson & Johnson

Janssen Biotech, Inc. [“Janssen”] today announced the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™ (ibrutinib) capsules for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.1 This indication is based on overall response rate (ORR). An improvement in survival or…

Quotient Clinical at AAPS 2013

6 November 2013 | By kdm communications limited

Quotient Clinical – the pioneer of Translational Pharmaceutics™ – will be showcasing the benefits of its unique, integrated approach to formulation development...